Stifel raises target for STAAR Surgical stock to USD 31.00
Stifel has upgraded STAAR Surgical (STAA) from Hold to Buy and increased its price target from USD 28.00 to USD 31.00 following strong second-quarter 2026 revenue and EPS results. The company also announced a USD 50.00 million share repurchase authorization. Stifel's positive outlook is based on anticipated sales of higher-priced EVO+ implantable Collamer lenses in China and easier international comparisons in the latter half of 2026.
STAAR Surgical: A Recovery Story Priced As Growth
STAAR Surgical faces significant concentration risk in China, with a large portion of its sales and receivables tied to two distributors. The company's valuation is considered premium despite limited cash generation and a single-product, single-market profile, leading to a "Sell" rating due to concerns about the sustainability of its growth assumptions. The article highlights that current trends do not support the assumed success in U.S./European markets, further emphasizing the risks.
STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upside
Stifel analyst Tom Stephan has upgraded STAAR Surgical Co. (NASDAQ: STAA) to Buy from Hold and raised the price target from $28 to $31, citing the company's potential for "meaningful upside" to Street estimates. Stephan projects STAAR Surgical to achieve 11% revenue growth CAGR between 2026 and 2028, surpassing the current consensus of 8%, driven by a rebound in China's refractive market and a shift towards higher-ASP EVO+ products. The analyst also notes the attractive entry point for the stock and the positive implications of the recently announced share repurchase authorization.
ETFs Investing in STAAR Surgical Company Stocks
This article lists various Exchange Traded Funds (ETFs) that hold STAAR Surgical Company (SR3) stocks, providing detailed financial information for each fund. The ETFs are primarily focused on small-cap and health care sectors, offering investors diverse opportunities with potentially lower risk. Key data points include market value, weight of SR3 stock, issuer, management style, expense ratio, and 3-year NAV total return.
STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know
Shares of STAAR Surgical (STAA) jumped 6.4% after Stifel upgraded the company from Hold to Buy, raising its price target to $31.00. The upgrade was driven by an anticipated revenue growth inflection in the second half of 2026, fueled by a favorable product mix in China and a recovering refractive market. Stifel projects an 11% compound annual sales growth rate for STAAR Surgical from 2026 to 2028, surpassing consensus estimates.
Why Staar Surgical Zoomed Almost 8% Higher on Tuesday
Staar Surgical (NASDAQ: STAA) shares rose nearly 8% after Stifel analyst Thomas Stephan upgraded the stock to "buy" from "hold" and increased his price target. Stephan anticipates higher sales for Staar's surgically implanted lenses, especially in China, and views the company as an attractive potential acquisition target and a strong developer of new products. The article highlights Staar's effective operation in its niche and its potential value for investors.
STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know
STAAR Surgical (STAA) shares surged 6.4% in pre-market trading after Stifel upgraded the company's stock from Hold to Buy and increased its price target to $31.00. The upgrade was driven by expectations of revenue growth in the latter half of 2026, fueled by a favorable product mix shift towards higher-priced lenses in China and a recovering refractive market. Stifel projects an 11% compound annual sales growth rate for STAAR Surgical from 2026 to 2028, surpassing consensus estimates.
Stifel upgrades STAAR Surgical stock rating on China growth outlook
Stifel upgraded STAAR Surgical (NASDAQ:STAA) to Buy from Hold, raising its price target to $31 from $28 due to anticipated sales growth in the second half of 2026, driven by China's EVO+ product mix shift and easier comparisons. The analyst projects significant revenue growth in China for 2027, further supported by the end of Middle East headwinds. The company shows strong momentum with 51% revenue growth and a 77% gross profit margin, holding more cash than debt.
STAAR Surgical Stock In Focus After $50 Million Buyback Plan
STAAR Surgical announced a US$50 million share repurchase program over 12 months, funded by free cash flow and cash on hand. This move emphasizes capital allocation for shareholder returns while the company's core implantable lens business faces challenges in key markets like China. Although the buyback doesn't fundamentally alter the market dynamics, it signals management's confidence in generating sufficient free cash flow.
STAAR Surgical Board Approves $50 Million Share Repurchase Program
STAAR Surgical Company's board of directors has authorized a share repurchase program of up to $50 million, funded by organic free cash flow and cash on hand. The decision reflects the board's confidence in the company's business progress, strong balance sheet, and belief that the stock is currently undervalued. The program highlights STAAR's commitment to capital allocation and shareholder value, with plans to run over the next 12 months.
STAAR Surgical Board Approves $50 Million Share Repurchase Program
STAAR Surgical Company announced its board of directors approved a share repurchase program of up to $50 million of outstanding common stock, funded by free cash flow and cash on hand. The company's CEO, Warren Foust, stated this decision reflects confidence in STAAR's business progress, strong balance sheet, ample free cash flow, and the belief that the company's shares are currently undervalued. This move is part of a disciplined capital allocation strategy to enhance shareholder value, alongside significant recent financial performance and key executive appointments.
STAAR Surgical Announces $50 Million Buyback Plan, Stock Soars More Than 7% on Friday
STAAR Surgical announced a $50 million stock buyback plan, causing its stock to rise over 7%. The company's CEO, Warren Foust, stated that the plan reflects confidence in the business, its strong balance sheet, ample free cash flow, and the belief that STAAR is currently undervalued. This move follows strong Q2 performance, including a doubling of net sales driven by growth in China and nearly $149 million in cash.
STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know
STAAR Surgical (STAA) shares surged 6.3% after the company announced a new share repurchase program of up to $50 million over the next twelve months. This news is seen by investors as a sign that management believes the stock is undervalued. Despite this recent jump, the stock has been volatile, and a recent industry warning about insurance changes affecting procedure growth has caused broader sector concerns.
Why Staar Surgical Stock Soared Today
Staar Surgical (STAA) stock jumped over 7% after announcing a $50 million share buyback program. The company's board believes the stock is undervalued and plans to repurchase shares over the next year. This move follows strong second-quarter results, where Staar Surgical more than doubled net sales and achieved a net profit, supported by a healthy cash position.
Staar Surgical Up 6% on $50M Share Buyback
Staar Surgical's stock rose 6% after the company's board of directors authorized a $50 million share repurchase program. CEO Warren Foust cited confidence in the company's business progress, strong balance sheet, and ample free cash flow, noting Staar has no outstanding debt and $181.5 million in cash and investments. The news led to a 6.3% increase in share price, bringing its market cap to $1 billion.
STAAR Surgical Names Former CEO David Bailey Chief Commercial Officer
STAAR Surgical has appointed former CEO David Bailey as its new Chief Commercial Officer. Bailey previously led the company from 2001 to 2008 and oversaw the FDA approval of the ICL in 2005, significantly contributing to the company's international growth. In his new role, he will focus on commercial opportunities for the EVO ICL in South and Southeast Asia, South America, and Africa.
STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
STAAR Surgical Company announced its Board of Directors authorized a share repurchase program of up to $50 million of its outstanding common stock. The company plans to repurchase shares over the next twelve months, funded by free cash flow and cash on hand. CEO Warren Foust stated the decision reflects confidence in STAAR's business progress, strong balance sheet, and a belief that the company is currently undervalued.
STAAR Surgical (STAA) Unveils Buyback, Is It Still Below Fair Value?
STAAR Surgical (STAA) has announced a new US$50 million share repurchase program, funded by free cash flow and cash on hand, amidst a significant decline in its share price over the past year. Despite an ongoing fiduciary investigation and competitive pressures, Simply Wall St's analysis suggests the stock is 36% undervalued, with a fair value of $29.67 compared to its current price of $19.08. The company possesses strong cash reserves and no debt, which could help navigate challenges, but it also faces risks due to its reliance on a single distributor in China.
STAAR Surgical stock ticks higher on $50M buyback authorization
STAAR Surgical Company (NASDAQ:STAA) shares rose after announcing a $50 million share repurchase program authorized by its Board of Directors. The medical device company plans to fund the repurchases using organic free cash flow and cash on hand, reflecting confidence in its business and balance sheet strength. The program is expected to continue over the next twelve months, with the timing and amount determined at the company's discretion.
STAAR Surgical authorizes $50 million share buyback program
STAAR Surgical Company has announced a new share repurchase program, authorizing the buyback of up to $50 million of its common stock. This move reflects the Board and management's confidence in the company's business progress, strong balance sheet, and free cash flow, with plans to fund repurchases using organic free cash flow and cash on hand. The program is expected to continue for the next twelve months, with the company maintaining flexibility regarding the timing, price, and amount of repurchases.
STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
STAAR Surgical Company has announced that its Board of Directors authorized a share repurchase program of up to $50 million of its outstanding common stock. The company believes its stock is "substantially undervalued" and plans to repurchase shares using organic free cash flow and its current cash reserves of $181.5 million, with the program expected to continue over the next twelve months. This decision reflects the company's confidence in its business progress, strong balance sheet, and commitment to shareholder value.
STAAR Surgical Company announces an Equity Buyback for $50 million worth of its shares.
STAAR Surgical Company has announced a share repurchase program, authorizing the buyback of up to $50 million worth of its shares. The program will be funded through organic free cash flow and cash on hand and is valid for 12 months. As of August 7, 2026, the company had 50.1 million outstanding shares.
Investigation launched into STAAR Surgical for possible fiduciary breaches affecting shareholders.
Levi & Korsinsky has initiated an investigation into STAAR Surgical Company concerning potential breaches of fiduciary duties, raising concerns about the company's management practices. This probe could lead to legal action or shareholder claims, impacting current investors who can seek further information or legal counsel at no cost. The article also provides a brief market snapshot for the health sector, noting that 78 out of 100 US health-sector stocks fell on September 24, 2026.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA).
Levi & Korsinsky, LLP has launched an investigation into STAAR Surgical Company (NASDAQ: STAA) regarding potential breaches of fiduciary duties by its officers and directors. Current shareholders of STAA are encouraged to request additional information about this investigation. The firm, specializing in securities litigation and financial fraud, represents investors nationwide and seeks to recover funds for aggrieved shareholders.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA).
Levi & Korsinsky, LLP has launched an investigation into STAAR Surgical Company (NASDAQ: STAA) regarding potential breaches of fiduciary duties by its officers and directors. Current shareholders of STAA are encouraged to seek additional information or contact the firm to learn more about the ongoing investigation. The firm specializes in securities litigation and aims to recover damages for aggrieved investors.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA).
Levi & Korsinsky, LLP has launched an investigation into STAAR Surgical Company (NASDAQ: STAA) regarding potential breaches of fiduciary duties by its officers and directors. Shareholders of STAA are encouraged to seek additional information about the ongoing inquiry. The firm specializes in securities litigation and represents investors nationwide.
STAAR Surgical Company (STAA) Stock Price, News, Quote & History
This article provides a comprehensive overview of STAAR Surgical Company (STAA), including its current stock price, financial performance, and company profile. It details the company's products, market statistics, earnings trends, analyst ratings, and key financial highlights. The article also compares STAAR's performance against the S&P 500 benchmark.
STAAR SURGICAL COMPANY : JEFFERIES CUTS TARGET PRICE TO $23 FROM $28
Jefferies has cut its target price for STAAR Surgical Company (STAA.O) shares to $23 from the previous $28. This information comes from a Reuters report dated September 22, 2026. The article itself serves as a brief financial news alert.
STAA Rated Buy by Jefferies -- Price Target Lowered to $23
Jefferies has maintained a "Buy" rating on Staar Surgical (STAA) but has lowered its price target to $23.00 from $28.00. This adjustment reflects a cautious outlook, despite GuruFocus indicating the stock is 37.9% undervalued with a GF Value™ of $33.37. Investors are advised to exercise caution due to the company's high P/E ratio and the "Possible Value Trap" label.
STAAR Surgical hires former CEO to lead commercial team
STAAR Surgical has appointed former CEO David Bailey as its new chief commercial officer. Bailey previously led STAAR from 2001 to 2008 and was instrumental in blocking Alcon's attempted takeover of the company last year. He plans to focus on growing sales in established markets and expanding into new patient populations globally.
STAAR Surgical Names David Bailey as Chief Commercial Officer with Detailed Compensation Package
STAAR Surgical Company has appointed David Bailey as Chief Commercial Officer, effective September 8, 2026. His compensation package includes an annual base salary of CHF 462,825 (approximately $575,000), a target cash bonus of 60% of his base salary, an initial RSU grant valued at $850,000, and a 2026 long-term incentive award worth $1,400,000. Bailey previously served as STAAR Surgical's CEO and President from 2001 to 2008 and is the founder of DB Consulting.
STAAR Surgical Rehires Former CEO David Bailey as Chief Commercial Officer
STAAR Surgical Company has reappointed its former CEO, David Bailey, as Chief Commercial Officer. Bailey, who previously led STAAR from 2001 to 2008, is recognized for his significant contributions to the commercialization of the EVO ICL and his extensive experience in the ophthalmology and medical technology sectors. His return aims to leverage his deep understanding of STAAR's technology to maximize its commercial potential, particularly as lens-based surgery gains market share from declining laser procedures.
STAAR Surgical Company Announces Appointment of David Bailey as Chief Commercial Officer
STAAR Surgical Company has announced the appointment of David Bailey as its new Chief Commercial Officer. Bailey brings extensive experience in ophthalmology and medical technology, having previously served as President and CEO of STAAR Surgical from 2001 to 2008, where he was instrumental in securing FDA approval for the ICL and driving international expansion. In his new role, he reports to Warren Foust, President and Chief Executive Officer.
STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
STAAR Surgical Company (NASDAQ: STAA) has appointed its former President and CEO, David Bailey, as Chief Commercial Officer. Bailey is credited with significantly impacting STAAR's global refractive transformation, especially with the commercialization and development of the EVO ICL. His return aims to accelerate the company's revenue growth and innovation roadmap, leveraging his extensive experience in ophthalmology and medical technology.
STAAR Surgical Company Announces Appointment of Ben Park as Chief Technology Officer
STAAR Surgical Company has announced the appointment of Ben Park, Ph.D., as its new Chief Technology Officer. Dr. Park, who joins STAAR's Executive Committee, previously served as Head of Emerging Technology at Align Technology Inc. He brings extensive experience in developing and launching health technology products globally, holding numerous patents and peer-reviewed publications.
STAAR Surgical Names Warren Foust President and Chief Executive Officer
STAAR Surgical has appointed Warren Foust as its new President and Chief Executive Officer, officially ending an interim leadership period. Foust, who previously served as Interim Co-CEO, President, and Chief Operating Officer, also joined the company's Board of Directors. He has been instrumental in overseeing various key departments and leading an operational reset for the company.
Total liabilities of STAAR Surgical Company – HAM:SR3
This page displays financial information for STAAR Surgical Company (HAM:SR3), specifically focusing on its total liabilities. The content appears to be a stub or a section of a larger financial data platform, showing headings for "Period," "Value," "Change," and "Change %" but without actual data filled in.
Total assets of STAAR Surgical Company – HAM:SR3
The article provides financial information for STAAR Surgical Company (HAM:SR3), specifically focusing on its total assets. It is a financial data page from TradingView, indicating that the market is closed for this stock and no trades have occurred. The content highlights where the data originates, including ICE Data Services and FactSet.
Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical
This article highlights several stocks that made significant movements this week, including Bally's, Adobe, Novavax, Semtech, and STAAR Surgical. Bally's rose due to a potential sale of development rights, Adobe increased after BlackRock raised its stake, and Novavax saw gains following positive trial results from peers. Semtech's stock climbed after selling its cellular module business, while STAAR Surgical experienced a decline due to underwhelming second-quarter earnings.
Madison Avenue Partners, LP Buys Staar Surgical Co (STAA) -- Shares Look 31% Undervalued on GF Value
Madison Avenue Partners, LP significantly increased its stake in Staar Surgical Co (STAA) by purchasing an additional 1,321,038 shares at $28.69 each, bringing its total holdings to 4,175,748 shares. This transaction, executed on June 30, 2026, represents a 1.62% portfolio impact and suggests Madison Avenue Partners believes in STAA's long-term intrinsic value despite a recent 19.64% decline in the stock price since the purchase. GuruFocus data classifies STAA as a "Possible Value Trap, Think Twice" but notes its GF Value of $33.51 indicates it is trading at a discount to its estimated intrinsic value.
5 Insightful Analyst Questions From STAAR Surgical’s Q2 Earnings Call
STAAR Surgical's Q2 results exceeded analyst expectations for revenue and adjusted earnings, driven by increased adoption of EVO Plus in China and market share gains. Despite the positive financial performance, the market reacted negatively, raising questions about growth sustainability. The article highlights key analyst questions and management responses regarding Q3 expectations, China growth, U.S. strategy, competition, and pricing power.
STAAR Surgical (STAA) exec's 6,599-share award, ownership corrected
STAAR Surgical's Chief Development Officer, Magda Michna, settled and exercised performance-based equity awards on August 14, 2026, acquiring 6,599 shares of common stock from PSUs. The company also corrected prior Form 4 filings to accurately reflect lower historical beneficial ownership values for Michna. This transaction involved shares withheld for taxes and payment of exercise price, as detailed in the SEC filing.
STAAR Surgical (STAA) links CEO options to $50–$100 hurdles
STAAR Surgical (STAA) has granted its President and CEO, Warren Foust, new equity awards including restricted stock units (RSUs) and stock options. A significant portion of these awards, specifically performance stock options for 255,489 shares, are tied to stock-price hurdles of $50.00, $75.00, and $100.00 per share, alongside time-based vesting. Additionally, 22,493 RSUs and other time-based stock options were granted, with some performance stock units from an earlier program also vesting and shares withheld for tax purposes.
Why STAAR Surgical (STAA) Shares Are Sliding Today
STAAR Surgical (NASDAQ:STAA) shares fell 8.3% after investors reacted negatively to mixed guidance following its Q2 earnings report, despite exceeding sales and EPS estimates. Stifel lowered its price target on STAA to $28 from $31, maintaining a Hold rating due to concerns about the "fragile" refractive market in China. The stock's current performance reflects investor concern over broader market conditions and recent industry warnings about potential slowdowns in medical procedures.
Stifel cuts Staar Surgical stock price target on China concerns
Stifel has lowered its price target for Staar Surgical Company (NASDAQ:STAA) to $28 from $31, while maintaining a Hold rating, citing concerns related to the China market despite positive aspects highlighted in the company's recent earnings call. Although the company reported strong second-quarter revenue that surpassed expectations, particularly from China, its earnings per share fell short of analyst projections. Other analysts, including Jefferies and Piper Sandler, have also adjusted their price targets or reiterated ratings, reflecting a cautious but not entirely negative outlook on the stock.
Stifel cuts Staar Surgical stock price target on China concerns
Stifel has lowered its price target for Staar Surgical Company (NASDAQ:STAA) to $28 from $31, while maintaining a Hold rating, citing concerns about the China market despite the company's strong second-quarter performance. The company's recent earnings call highlighted positive trends including China share gains and EVO+ momentum, and it comfortably aligns with Street estimates for Q3 and fiscal year 2026 revenue. Despite robust growth in China contributing significantly to revenue, the firm noted that the China refractive end market still appears fragile.
STAAR Surgical (NASDAQ:STAA) Shares Down 6.6% Following Analyst Downgrade
STAAR Surgical (NASDAQ:STAA) shares dropped 6.6% after Stifel Nicolaus lowered its price target from $31 to $28 while maintaining a hold rating. The company's stock now has a consensus "Hold" rating and an average price target of $28.40 from analysts. Despite exceeding revenue expectations with $93.53 million, the company missed earnings estimates, reporting $0.16 EPS against an expected $0.22.
Why STAAR Surgical (STAA) Is Up 8.1% After Returning To Profit Under New CEO Warren Foust – And What's Next
STAAR Surgical (STAA) reported a significant return to profitability in Q2 2026 with sales of US$93.54 million and net income of US$8.06 million, reversing previous losses. This turnaround coincides with Warren Foust's appointment as CEO, leading to a positive market reaction with the stock up 8.1%. The company's future investment narrative focuses on the sustainability of these improved volumes and margins, especially concerning inventory management in China and global growth.
STAAR Surgical (STAA) Gives Warren Foust The CEO Role After Its Profit Reset
STAAR Surgical has appointed Warren Foust as its permanent President and CEO, following a period of operational reset and a return to profitable growth under his interim leadership. Foust's promotion from COO and interim co-CEO signifies a defined leadership direction for the ophthalmic device maker. Investors will be watching for sustained profitability, China revenue trends, and EVO+ uptake to assess the success of this leadership change.
Quantinno Capital Management LP Takes $1.11 Million Position in STAAR Surgical Company $STAA
Quantinno Capital Management LP has acquired a new position in STAAR Surgical Company, purchasing 59,302 shares valued at approximately $1.11 million. This makes Quantinno Capital Management LP a 0.12% stakeholder in the company, which has seen its revenue increase by 111.1% year-over-year in the latest quarter, though its earnings per share missed analyst expectations. Institutional investors and hedge funds now collectively own 96.70% of STAAR Surgical, with analyst sentiment remaining mixed with an average "Hold" rating.
